Ipsen sales and marketing update

Ipsen said it expects a supply interruption of Increlex mecasermin in the U.S. this quarter and in Europe and the rest of the world next quarter due to undisclosed manufacturing issues. Ipsen said its supplier, Lonza Group Ltd. (SIX:LONN, Basel, Switzerland), is experiencing manufacturing issues at its Hopkinton, Mass. facility and is working with FDA to address these issues. Ipsen said it does not anticipate re-supply of the recombinant human insulin-like growth factor-1 ( IGF-1) before year end. The partners declined to disclose details. ...